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Epidermal growth factor (EGF) has been purified from human milk. The purification was monitored with 
a human placental membrane radioreceptor assay using murine salivary epidermal growth factor I (mEGF 
I) as a competitive ligand and was achieved exclusively by the use of reverse-phase liquid chromatography 
(RPLC). The sequential use of preparative, semipreparative and analytical RPLC on an octylsilica support 
with solvent systems of different solute selectivity such as pyridine formate, triethylammonnium phosphate 
or perfluorocarbonic acids in the presence of n-propanol or acetonitrile allowed purification to homogeneity 
with 5 consecutive runs. The molecular mass, amino acid composition and NH,-terminal sequence of human 
EGF were determined. Gas-phase microsequencing of residues 1-17 revealed the following sequence: Asn- 
Ser-Asp-Ser-Glu-X-Pro-Leu-Ser-His-Asp-Gly-Tyr-X-Leu-X-Asp which is identical with the NH,-terminof 
urogastrone from human urine. The purified polypeptide competes with mEGF for the placental membrane 
receptor with a k, of 1 ng. Furthermore, it stimulates the anchorage-dependent as well as -independent 
proliferation of human and rat indicator cells with half-maximal stimulation at 1 and 2.5 ng/ml, respectively. 
Although human epidermal growth factor has been unequivocally identified in human milk and - for the 
first time - shown to be identical with urogastrone from human urine, the high-resolution techniques 
employed have also revealed the presence of EGF-related molecules which await further characterization. 
It is possible that EGF and the EGF-related growth factors possess important regulatory functions in 
normal growth of the human breast during pregnancy and lactation as well as in abnormal growth during 
mammary tumor formation and progression. 
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1. INTRODUCTION 
While working on the purification of nerve 
growth factor (NGF) from the submaxillary gland 
of the mouse, Cohen [l] observed that daily injec- 
tions of certain gland extract fractions into 
newborn mice produced developmental effects 
which he could not ascribe to the presence of NGF. 
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These effects included precocious opening of the 
eyelids and early eruption of the incisors. Using 
these gross anatomical effects as a biological assay 
he was able to isolate the factor responsible, a 
polypeptide which he named epidermal growth 
factor (EGF) [2] and - a decade later - deciphered 
its complete amino acid sequence [3]. 
In 1975, Gregory [4] reported the isolation and 
characterization of urogastrone, an inhibitory 
polypeptide of gastric acid secretion present in 
human urine. Surprisingly, when the primary 
structure of urogastrone was compared with those 
of other fully characterized polypeptides a 
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remarkable structural similarity with murine EGF 
became evident. Of the 53 amino acid residues 
comprising urogastrone and mEGF, 37 are iden- 
tical. This homology prompted Gregory to test 
human urogastrone for eyelid opening activity in 
mice and mEGF for antisecretory activity in rats 
and dogs. Since murine EGF inhibited gastric acid 
secretion and, in turn, urogastrone was capable of 
inducing eyelid opening in newborn mice, it is 
generally assumed, although not proven, that both 
biological activities reside in one molecule, i.e. that 
in the human urogastrone and EGF are identical 
[41. 
To investigate further the relationship of 
urogastrone and human EGF, we decided to deter- 
mine the chemical structure of EGF from a body 
fluid other than urine as source of urogastrone. 
Since EGF activity had also been detected in 
serum, saliva, amniotic fluid and milk [5], the lat- 
ter fluid was chosen as starting material. Milk is a 
complex fluid resembling blood in many regards 
since it contains a large variety of macromolecules 
including hormones (e.g., adrenocorticotropic 
hormone, erythropoietin and prolactin) and dif- 
ferent cell types such as T- and B-lymphocytes, 
macrophages, neutrophils and occasionally 
epithelial cells [6]. The growth promoting activity 
for human fibroblasts in vitro which is present in 
milk [7] has been attributed in part to the presence 
of an EGF-like polypeptide [B] which was later 
identified in human but not in bovine milk [9]. 
We report here that acidified milk - upon frac- 
tionation on reverse-phase supports - contains 4 
polypeptides (A-D) capable of competing with 
murine EGF for human placental membrane 
receptors and of inducing DNA synthesis in 
cultured human skin fibroblasts. In addition, these 
polypeptides timulate the replication of rat kidney 
fibroblasts grown in semisolid media. Hence, they 
belong to a group of regulatory polypeptides, the 
transforming growth factors (TGFs), that induce 
anchorage-independent growth of normal cells the 
proliferation of which is usually anchorage- 
dependent [lo]. We have purified the polypeptide 
present in largest quantity (TGFu) to homogeneity 
and determined its molecular mass, amino acid 
composition, partial NHz-terminal sequence and 
biological activities. Our results strongly support 
the assumption that TGFu is EGF and that human 
urogastrone and EGF are identical. 
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2. MATERIALS AND METHODS 
2.1. Human milk 
Samples of human milk were obtained from the 
Mothers’ Milk bank in San Jose, CA and stored at 
-20°C until use. 
2.2. Cell culture 
Human foreskin fibroblasts were prepared by 
trypsinization of foreskin and were subsequently 
passaged in cell culture. Fibroblasts that had been 
transferred 3 or 4 times after primary cultures were 
used for DNA-synthesis experiments. Natural rat 
kidney fibroblasts (NRK, clone 49F) were obtained 
from the American Type Tissue Culture Associa- 
tion (Rockville, MD). After initial thawing and 
plating the cells were passaged every 3 days. Fresh 
cultures were initiated from liquid nitrogen storage 
every 2 months. 
2.3. DNA synthesis 
Subconfluent monolayers of human foreskin 
fibroblasts were trypsinized and resuspended in 
Dulbecco’s modified Eagle’s medium (DMEM) 
(glucose concentration 4.5 g/l) containing 5% 
fetal calf serum (Gibco) at 2.5 x lo4 cells/ml. The 
assay was performed as decribed [l l] except that 
glucocorticoids were omitted and the fetal calf 
serum concentration raised to 0.4%. The cells were 
harvested on, filter paper using a PHD cell 
harvester (Cambridge Technology, Cambridge, 
MA) and DNA synthesis measured by scintillation 
counting. 
2.4. Colony formation in soft agar 
The soft agar assay was performed in a 
microculture assay system: aliquots of 250~1 of 
0.8% agar (Seaplaque, FMC Labs, Rockland, ME) 
in DMEM containing 10% fetal calf serum and 
supplemented with penicillin (100 U/ml), fungi- 
zone (0.25 pug/ml), streptomycin (100 U/ml) and 
glutamine (2 mM) were pipetted into the wells of 
multiwell tissue culture plates (Falcon, Oxnard, 
CA). After the agar had solidified, a second 200 ~1 
layer containing 5000 NRK cells in 0.4% agar and 
DMEM supplemented with 10% fetal calf serum 
and antibiotics was added. Subsequently, a third 
50 ~1 layer containing the polypeptide to be tested 
was added. Before seeding, the cell suspension was 
thoroughly pipetted with a 20 gauge needle to 
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remove clumps of cells which can cause spurious 
colony formation. The tissue culture plates were 
placed in a humidified incubator at 37°C with 5% 
CO2 for lo-14 days; rectangular fields of 0.5 cm’ 
were then screened for colonies larger than 68 pm 
in diameter. 
2.5. Polypeptide isolation 
The chromatography system has been described 
[ 121. Reverse-phase columns were either prepared 
in our laboratory with Lichroprep (RP 8, 2.5 x 
6.0 cm, particle size 15-25 pm, pore size 100 A, 
Merck, Darmstadt) as reported [13] or obtained 
prepacked from Brownlee Laboratories (RP 300, 
0.7 or 0.46 x 25 cm, particle size lOpm, pore size 
300 A, Santa Clara, CA). Column eluates were 
monitored with a fluorometric postcolumn 
derivatization system [14] and/or by UV absor- 
bance at 280 nm. Mobile phases utilized were 
0.36 M pyridine formate (pH 3.0), 0.25 M 
triethylammonium phosphate (pH 3 .O) [ 151, 0.1% 
trifluoroaceteic acid (TFA) (pH 2.10) or 0.05% 
heptafluorobutyric acid pH 2.48) [16]. n-Propanol 
or acetonitrile were used as organic modifiers. 
For isolation batches of 400 ml milk were 
thawed, acidified by the addition of 200 ml glacial 
acetic acid and centrifuged for 30 min at 100000 x 
g. After centrifugation the pellet containing 
cellular debris and the creamy top layer were 
discarded and the resulting liquid filtered through 
nylon gauze. After adjustment to pH 3.0 with 
pyridine formate the acidified milk was directly 
pumped onto the preparative RPLC system. 
2.6. Preparation and iodination of murine EGF I 
Murine EGF I was prepared and iodinated as 
described [ 171. 
2.7. Radioreceptor assay for EGF 
Placental membranes were prepared as describ- 
ed by Hirata and Orth [ 181. The binding assay was 
carried out using 400~1 polyethylene tubes; after 
the addition of 200 ,ul of a mixture of known stan- 
dard or unknown sample and 1251-mEGF-I tracer 
(spec. act. 100 cpm/pg), 100 ~1 membrane solution 
was added. After 45 min incubation at 4°C the 
tubes were centrifuged for 5 min at 7500 x g at 
4°C and immediately frozen in dry ice/ethanol. 
The pellet containing the membranes was obtained 
by cutting the bottom part of the tubes and 
counted in a Gamma 9000 Counter (Beckman In- 
struments, Fullerton, CA). In the assay a standard 
curve was obtained in triplicate in the concentra- 
tion range of 150 pg to 30 ng per tube. Samples 
with unknown amounts were determined in 
duplicates. 
2.8. SDS gel electrophoresis 
Peptides were dissolved in sample buffer and 
analyzed in a discontinuous slab gel system (20% 
polyacrylamide) in the presence or absence of 
50 mM dithiothreitol [ 191. After electrophoresis 
one half of the gel was cut into 1 mm slices and the 
polypeptides eluted by shaking overnight at 4°C in 
I .O ml of buffer containing 125 mM Tris-Cl, 
1 mM EDTA and 2 mg bovine serum albumin. 
Two aliquots of 190~1 each were then tested for 
the presence of active material in the radioreceptor 
assay. The remainder of the gel was stained with 
silver [20]. 
2.9. Amino acid analysis and sequencing 
Peptide aliquots of lo-20 pmol were subjected 
to hydrolysis and analyzed with a Liquimat III 
(Kontron, Zurich) amino acid analyzer [21]. Gas- 
phase sequence analyses were performed as 
reported [22] except for the implementation of a 
new software program obviating the need for a 
vacuum system in the gas-phase sequencer 
(designated 02NVAC and supplied by Applied 
Biosystems, Foster City, CA). Also, the resultant 
PhNCS-amino acid residues were identified using 
an improved RPLC separation system suggested 
by W. Touchstone (Baylor College, Houston) and 
M. Hunkapiller (Applied Biosystems). 
3. RESULTS 
3.1. Purification of TGFD 
Preparative RPLC of acidified milk (from one 
individual donor) revealed two radioreceptor ac- 
tive fractions (pools I and II) eluting at 20.4 and 
22.2% n-propanol (not shown). Both pools were 
individually rechromatographed in the same sol- 
vent system on a semipreparative RP 300 column 
using a linear gradient from 10 to 18% n-propanol. 
Under these conditions the activity present in pool 
I was separated into two bioactive fractions eluting 
at 14.4 and 14.7% n-propanol which were 
designated TGFA and TGFB (fig.1, upper). 
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Fig. 1. Semipreparative RPLC of pools I and II from preparative column. Pool I (upper trace) and pool II (lower trace) 
were loaded after 1 : 1 dilution with pyridine formate on a semipreparative RF 300 column in pyridine formate (pH 3.0). 
The column was eluted with a linear gradient from 10 to 18% n-propanol over 240 min. Flow rate was 1.0 ml/min. 
3 ml fractions were collected and 30~1 aliquots used for the radioreceptor assay. The horizontal bars indicate the 
presence of radioreceptor active material. 
Chromatography of pool II led to the appearance 
of two TGFs which eluted at 15.9% (TGFc) and 
16.5% (TGFn) n-propanol (fig.1, lower). The lat- 
ter molecule was further purified on an analytical 
RP 300 column using an acetonitrile gradient from 
28 to 32% (over 90 min) in 0.1% TFA as mobile 
phase (fig.2A). The bioactive fractions were 
pooled and rechromatographed on the same 
column using triethylammonium phosphate as 
buffer and eluting the polypeptides with an 
acetonitrile gradient from 21 to 27% over 120 min. 
In such a system TGFD is less hydrophobic and 
elutes at about 24% acetonitrile (not shown). Final 
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purification was achieved in 0.05% heptafluoro- 
butyric acid where TGFn is more hydrophobic 
than in TFA and elutes at about 32% acetonitrile 
(fig.2B). The molecule was considered better than 
90% pure as judged by the appearance of one sym- 
metrical peak in two solvent systems with different 
solute selectively, i.e. in 0.05% heptafluorobutyric 
acid and rechromatography in 0.1% TFA. 
In addition, the purity was subsequently con- 
firmed by analytical gel electrophoresis and gas- 
phase sequencing (see below). From 30 g protein 
present in 3000 ml acidified milk, 12 pg (2 nmol) 
TGFb was obtained in highly purified form. 
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Fig.2. Further purification of TGFn on an analytical 
RP 300 column in 0.1% trifluoroacetic acid (pH 2.10) 
(A) and final purification in 0.05% heptafluorobutyric 
acid (pH 2.48) (B). Flow rate 0.5 ml/min. 1.5 ml 
fractions were collected and 15 81 aliquots removed for 
the radioreceptor assay. The horizontal bars indicate the 
presence of radioreceptor active material. 
Table 1 
Amino acid analysis of TGFn 
Asx 
Thr 
Ser 
GlX 
GlY 
Ala 
Val 
Met 
Ile 
Leu 
Tyr 
Phe 
His 
Trp 
LYS 
Arg 
Cysb 
Pro 
TGFn Urogastrone= 
6.30 f 0.32 7 
0 0 
3.18 + 0.75 3 
5.85 f 0.32 5 
4.33 f 0.43 4 
2.17 f 0.87 2 
3.56 + 0.37 3 
1.01 + 0.10 1 
1.91 f 0.25 2 
5.76 f 0.91 5 
5.81 f 0.89 5 
0 0 
1.14 f 0.37 2 
0.92 f 0.15 2 
2.14 -+ 0.42 2 
2.60 k 0.24 3 
5.36 f 0.63 6 
2.31 + 0.23 1 
a I41 
b Determined as cysteic acid 
Data are expressed as residues per molecule assuming an 
Mr of about 6000. Values are means + SD of 3 
determinations and are not corrected for hydrolysis 
losses 
3.2. Molecular mass, amino acid composition and 
NH2-terminal sequence of TGFD 
Highly purified TGFn migrated as a single band 
with an apparent M, = 6000 in SDS-polyacryl- 
amide gel electrophoresis as determined by silver 
staining of the gel. The same migration pattern was 
obtained in the absence of reducing agent. The 
specific association of this band with radioreceptor 
competing activity was proven by slicing a parallel 
unstained gel track that contained unreduced sam- 
ple. 1 mm slices prepared from this track were ex- 
tracted overnight and extracts were assayed for 
EGF competing activity in the receptor assay. All 
the extracted radioreceptor activity was found to 
migrate in the 6.0 kDa region of the gel (not 
shown). 
The amino acid composition of TGFn isolated 
from human milk is shown in table 1. Values were 
calculated assuming an &I, of 6000. 
Automated Edman degradation of TGFn was 
performed with 300 pmol sample (based upon 
amino acid composition). An initial yield of 79.7% 
and an average repetitive yield of 82.3% were ob- 
loo 1 
y 
ii l! 
6 lo 15 20 
CYCLE NUMBER 
Fig.3. Gas-phase sequence analysis of 300 pmol TGFn. 
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tained. Unambiguous identification of phenyl- 
hydantoin derivatives of amino acids was possible 
up to residue 17 (fig.3). Cysteine residues were not 
positively identified (e.g., by preparing the S- 
alkylated derivatives) in this analysis, but no other 
residues were identified at cycles 6, 14 and 16. 
Based on this analysis the partial sequence deter- 
mined of TGFn corresponds exactly to residues 
1-17 of the sequence of human urogastrone. 
3.3. Biological activities of TGFD 
RPLC purified TGFo whose concentration had 
been determined by amino acid analysis stimulated 
DNA synthesis in a dose-dependent manner: half- 
maximal stimulation occurred at a concentration 
of 1 ng/ml with a 150% increase over control (i.e. 
with no polypeptide added) at maximal stimulation 
(fig.4). Because colony formation is a more critical 
evaluation of growth promoting activity than a 
z IA 1 
I ,// 
I \r TGFO 
-1 B 
PEPTIDE (t-q/ml) 
Fig.4. Biological activities of RPLC-purified TGFo. 
Effect upon thymidine incorporation in human foreskin 
fibroblasts (A) and colony formation of rat kidney 
fibroblasts grown in semisolid media (B). Values are 
means f SD of 6 determinations. 
system which measures the ability to stimulate 
[3H]thymidine uptake, the activity of the polypep- 
tide was also tested in an anchorage independent 
system with rat kidney fibroblasts: half-maximal 
stimulation was obtained with a concentration of 
2.5 ng/ml with the formation of 25 + 5 colonies 
per 0.5 cm’ field at maximal stimulation (fig.4). In 
the placental membrane receptor binding assay, 
TGFn caused a dose-dependent displacement of 
‘251-mEGF-I with a k, of 1 ng when a concentra- 
tion range of 0.15-7.5 ng/tube was tested. 
4. DISCUSSION 
The experiments reported here indicate that 
human milk contains several polypeptides that are 
able to compete with mEGF-I for human placental 
membrane receptors. One of them, TGFn, has 
been purified to homogeneity with an approach 
which is novel in that it is entirely based upon 
reverse-phase liquid chromatography. The use of 
solvent systems with different solute selectivity has 
allowed the rapid isolation of this low-abundance 
polypeptide from a complex mixture of biological 
compounds. The amino acid composition of TGFn 
is nearly identical with that of human urogastrone. 
In fact, the small differences in the amino acid 
compositions of the two polypeptides may be 
ascribed to ‘inaccuracies associated with the 
hydrolysis of very small amounts of polypeptide, 
i.e. less than 20 pmol [21]. Since NHz-terminal 
microsequencing of TGFD revealed a structure 
identical to that of human urogastrone it is very 
likely that TGFo is human EGF and identical with 
human urogastrone. Our studies also show that 
human milk contains several other EGF-like 
transforming growth factors. Similarly, Kimball et 
al. [23] have recently reported that urine from nor- 
mal individuals and cancer patients contain at least 
5 EGF-related TGFs and that there are distinct dif- 
ferences with regard to the relative levels of these 
molecules in cancer patients and normal controls. 
Complete purification and characterization of the 
TGFs present in human milk as well as urine are 
necessary to establish the molecular nature of these 
functionally related factors. Preliminary ex- 
periments from our laboratories have indicated 
that the other TGFs in human milk are biologically 
and chemically distinct from TGFD [24]. 
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The origin of EGF and the other EGF-related 
polypeptides in milk is not yet known. They could 
be released from the cells present in milk such as 
macrophages, lymphocytes, neutrophils or 
epithelial cells. Alternatively, the human breast, a 
society of interacting epithelial, myoepithelial, 
stromal connective tissue and vascular bed cells 
which proliferate when the mammary gland grows 
to its functional state during pregnancy and lacta- 
tion could produce and utilize these factors for 
auto- and paracrine regulation of the proliferative 
activity of its cells. This idea is supported by the 
finding that in early lactation a wave of epithelial 
proliferation is observed [25] and simultaneously 
colostrum is produced which contains larger 
amounts of growth promoting activity than milk 
[8]. As neoplastic transformation is considered by 
some authors [26] to be a caricature of the renewal 
or growth of normal tissue it could also be that the 
transforming growth factors in milk (including 
EGF) play an important role in mammary tumor 
development, for instance through their inap- 
propriate or constitutive expression by the 
neoplastic cell(s). In agreement with this possibility 
is the recent identification of EGF-like transform- 
ing growth factors and of EGF-receptors in human 
breast cancer cells 1271. 
Efficient microtechniques such as the one 
presented here should facilitate the characteriza- 
tion of such growth regulating factors from breast 
milk, mammary tumor tissue as well as tumor cell 
lines and allow one to define in molecular terms 
their relationship as a basis for a better understan- 
ding of the (normal) proliferation of human breast 
cells during pregnancy and lactation and the (ab- 
normal) proliferation during breast tumor forma- 
tion and progression. 
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